

## Patient Evidence Collected for pCODR and INESSS Drug Approval Processes

Date	Drug	Request	pCODR Recommendation
April 2012	Bendamustine / Treanda	For treated patients	Not recommended
April 2012	Bendamustine / Treanda	For untreated patients	Recommended
June 2014	Bendamustine	For untreated patients in combination w rituximab	Withdrawn by manufacturer
Aug 2014	Obinutuzumab / Gazyva	For untreated patients in combination w chlorambucil*	Recommended
April 2015	Ofatumumab / Arzerra	For untreated patients in combination w chlorambucil	Not recommended
Aug 2014	Ibrutinib / Imbruvica	For treated patients with or without 17p*	Recommended
April 2015	Idelalisib / Zydelig	For treated patients in combination with rituximab*	Recommended
April 2016	Ibrutinib	For untreated patients	Recommended
July 2016	Venetoclax	For treated patients with 17p deletion	Withdrawn by manufacturer
June 2017	Venetoclax	For treated patients who have failed a B-Cell Receptor Inhibitor (BCRi)**	In process

\* with Leukemia and Lymphoma Society of Canada

\*\* with Lymphoma Canada